阿爾凱默斯 ALKS 深 滬
已收盤 04-02 16:00:00 美东时间
34.84
-0.210
-0.60%
華盛通- 最 高35.32
- 今 開34.58
- 成交量 248.56万股
- 最 低 34.31
- 昨 收 35.05
- 總市值 58.06亿
- 52周最高 36.48
- 市盈率 靜 24.33
- 換手率 1.49%
- 52周最低 25.165
- 委 比 91.86%
- 總股本 1.67亿
- 歷史最高 79.041
- 量 比 0.50
- 振 幅 2.88%
- 歷史最低 10.311
- 每 手 1
- 風險率 2.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 April 1 (Reuters) - Wall Street's main indexes were set for a higher open
04-01 21:14
Alkermes Initiates Brilliance Studies Phase 3 Program Of Alixorexton For Adults With Narcolepsy Type 1 and Type 2
Alkermes plc (NASDAQ:ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and
04-01 19:20
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.
03-31 21:57
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Piper Sandler Maintains Overweight on Alkermes, Lowers Price Target to $43
Piper Sandler analyst David Amsellem maintains Alkermes (NASDAQ:ALKS) with a Overweight and lowers the price target from $45 to $43.
03-24 21:01
生物科技公司高管对特朗普药品定价计划发出警告
随着国会考虑是否执行特朗普总统提出的最惠国药品定价政策，一些生物科技公司高管开始公开反对这一措施——尽管整个行业普遍担心公开反对总统可能带来风险。 上市...
03-11 22:53
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics Inc. has appointed Susan Rodriguez as Chief Commercial and Strategy Officer. In this role, she will lead the company's commercial strategy and infrastructure development as it prepares to submit an NDA for ALXN1840, its investigational therapy for Wilson disease. With over 30 years of experience in biopharmaceutical leadership, Rodriguez brings a proven track record of successfully launching rare disease therapies and scaling...
03-02 13:00
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
H.C. Wainwright Reaffirms Their Hold Rating on Alkermes (ALKS)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold...
02-25 23:57
财报速睇 | 阿尔凯默斯 2025财年年度营收14.76亿美元，同比下降5.3%；归母净利润2.42亿美元，同比下滑34.1%
华盛资讯2月25日讯，阿尔凯默斯公布2025财年年度业绩，公司年度营收14.76亿美元，同比下降5.3%，归母净利润2.42亿美元，同比下滑34.1%。
02-25 23:02
